immatics biotechnologies, a cancer vaccines firm, has appointed Peter Chambré as chairman of the board with immediate effect.

Chambré has an extensive senior management experience in the biopharmaceutical sector and now holds several chairman positions in the life sciences industry. He will replace Thomas Widmann, who has been chairman of the company since 2004.

Chambré was chief executive of Cambridge Antibody Technology (CAT) from 2002 until its acquisition by AstraZeneca in 2006.

Before joining CAT, Chambré was chief operating officer of Celera Genomics Group and, previously, head of Bespak, a drug delivery company.

From 2008-2010, he was chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter in March 2010, and from 2006-2012, non-executive director of BTG.

He currently holds chairman and non-executive board roles with a number of companies.